

## CALL for a POST-DOCTORAL FELLOWSHIP,

## **CLERMONT-FERRAND, FRANCE**

IMoST Laboratory (Imaging Molecular and Theranostic Strategies <u>https://imost.uca.fr</u>) is a Research Center in Clermont-Ferrand supported by the Clermont-Auvergne University (UCA) , and INSERM institution (Institut National de la Santé et de la Recherche Médicale). The research center (1500 m<sup>2</sup> laboratory) is located in Clermont Ferrand, closely to the Comprehensive Cancer Center (Centre Jean Perrin, , <u>https://www.cip.fr/</u>). The research strategy of IMoST is the development of health technologic tools including the first into humans proof concept in shorter delays, for targeting *in vivo* tissular biomarkers, for both diagnosis and personalized therapy, mainly in oncology and exploiting radiopharmaceuticals. The unit brings together specialists of multidisciplinary skills (chemistry, radiochemistry, specialists in preclinical imaging, nuclear medicine,



oncology and biopathology), as well as high technology platforms, which creates a scientific environment, from chemistry to clinics; favourable to high inter-relations from bench to bed and from bed to bench.

UMR 1240 INSERM IMoST is based on a two teams structure entitled respectively Tatoo (Targets and Tools for imaging and therapy) and Robust (Research in functional imaging, radiopharmaceuticals and theranostic biomarkers). Team Tatoo has in charge the development and validation of innovative theranostic radiopharmaceutical tools in preclinical models, while Robust is focused on first into humans, as well as the identification of new targets and tissular biomarkers from patient biopsies. UMR 1240 INSERM is composed of 81 permanents members and 19 phD students.

Members of IMoST have an international expertise biomarkers, as well as a recognized and long term expertise in radiopharmaceuticals and radiolabelling with a wide range of radionuclide being used (<sup>64</sup>Cu, <sup>68</sup>Ga, <sup>18</sup>F, <sup>99m</sup>Tc, <sup>111</sup>In, <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>131</sup>I, <sup>177</sup>Lu,...).

All investigators are backed by basic to cutting-edge equipment from chemistry to clinics :from in organic and analytical chemistry, radiochemistry (shielded hot cells), genomics and proteomics (nanostring analyzer, laser microdissection), cellular L2 culture rooms, autoradiography, and small animal imaging (Optics, SPECT-CT, PET and CT).

Equipment for *in vivo* small animal imaging are integrated in a "multi-scale" imaging platform called "In Vivo Imaging in Auvergne" (IVIA), labellised at national scale (IBISA).

For first into humans of radiopharmaceutical, UMR 1240 INSERM works in close interaction with the CIRMEN (Research and Innovative Center in Nuclear medicine), one of the rare structures in France dedicated for clinical transfert of radiopharmaceuticals for imaging and targeted radionuclide therapy.

<u>UMR 1240 INSERM wishes to recruit a candidate to a post-doctoral</u> fellowship program of 3 years on human mobility and health. As part of the iSITE CAP20-25 initiative – challenge 3 « personalized human mobility for a better health », the successful candidate will benefit from a



## 🌐 Inserm

EUR 300k€ package (EUR 100k€/year for 3 years). This package includes 3 years post doc salary as well as running costs for the proposed project (For more details : https://cap2025.fr/recherche/challenges-scientifiques/la-mobilite-personnalisee-comme-facteur-cle-de-la-sante/postdoctoral-research-fellowship-program) :

The UMR 1240 INSERM will assist successful high level candidates to compete for a permanent research position in a French research institution as well as for external funding (competitive grants). Researchers having expertise in preclinical imaging and radiopharmaceuticals are strongly encouraged to candidate.

Candidates must have completed at least 3 years of postdoctoral training in a country different from the one of their PhD graduation.

Candidates currently holding a post-doctoral position in Clermont-Ferrand are not eligible. Applications should include a *cv*, a short description of achievements and a record of self-financing. We encourage both young and already established outstanding researchers to apply.

The final deadline for applications is May, 15th, 2023 (no file transmitted beyond this date/time will be evaluated).

Please send your application as a single PDF file of approximately 3-6 pages to <u>direction.imost@uca.fr</u>.

## ANNEXE

\* Synthetic summary of the thematic objectives of Mobility Challenge in health:

« Individual locomotion impacts autonomy, a key factor of human health and of special concern in the context of ageing. Preserving an active locomotor system as long as possible thus has a major influence on the quality of human life...To address the issue of individual mobility we consider that an integrative approach combining exploration of both the muscular system and locomotor apparatus and function needs to be considered. The Scientific Research is based on multidisciplinary approaches, strong public-private partnerships and aims at completing complementary objectives at the medical, technical, economic and social levels, which will allow a deeper understanding of the musculoskeletal system involved in mobility in both normal and pathological situations.

i) We will assess the metabolic responses to exercise and to nutritional and hormonal factors associated with reduced mobility in order to identify biomarkers of altered conditions of locomotion. Results will lead to the development of preventive and curative nutritional strategies<del>.</del>